CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Drug Therapies for the Long-Term Prophylaxis of Hereditary Angioedema Attacks

Last updated: December 19, 2019
Project Number: OB0007-000
Product Line: Technology Review
Result type: Report

Hereditary angioedema (HAE) is associated with often unpredictable attacks. These may be painful and impact a person’s ability to perform daily activities, such as working or attending school. Attacks with laryngeal involvement may lead to death. Plasma-derived C1-esterase inhibitor (C1-INH) products constitute the main therapy for treating and preventing these attacks. Their utilization is rapidly increasing in Canada. Other non-plasma-derived products are also becoming available for this condition.

The purpose of this project includes the following elements: improving the understanding of the context of drug therapies’ use for the long-term prophylaxis of HAE attacks, quantifying the utilization of C1-INH products, determining the economic value of plasma-derived and non-plasma-derived products for the long-term prophylaxis of HAE attacks, and determining the budget impact of funding these therapies.